Mazzara G.P. Velthuizen R.P. Pearlman J.L. et al.

Brain tumor target volume determination for radiation treatment planning through automated MRI segmentation.

Int J Radiat Oncol Biol Phys. 59: 300-312Lagendijk J.J. Raaymakers B.W. van Vulpen M.

The magnetic resonance imaging-linac system.

Semin Radiat Oncol. 24: 207-209Turgeon G.A. Iravani A. Akhurst T. et al.

What (18)F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?.

J Nucl Med. 60: 328-334Kalff V. Hicks R.J. MacManus M.P. et al.

Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.

J Clin Oncol. 19: 111-118Mac Manus M.P. Wong K. Hicks R.J. et al.

Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center.

Int J Radiat Oncol Biol Phys. 52: 351-361

BGRT: Biologically guided radiation therapy-The future is fast approaching.

Med Phys. 34: 3739-3751Machtay M. Duan F. Siegel B.A. et al.

Prediction of Survival by F18 Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial.

J Clin Oncol. 31: 3823-3830Lister T. Crowther D. Sutcliffe S. et al.

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

J Clin Oncol. 7: 1630-1636Cheson B.D. Horning S.J. Coiffier B. et al.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas.

J Clin Oncol. 17: 1244Cheson B.D. Pfistner B. Juweid M.E. et al.

Revised response criteria for malignant lymphoma.

J Clin Oncol. 25: 579-586Cheson B.D. Fisher R.I. Barrington S.F. et al.

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.

J Clin Oncol. 32: 3059-3067Juweid M.E. Wiseman G.A. Vose J.M. et al.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

J Clin Oncol. 23: 4652-4661Ceriani L. Martelli M. Gospodarowicz M.K. et al.

Positron emission tomography/computed tomography assessment after immunochemotherapy and irradiation using the Lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma.

Int J Radiat Oncol Biol Phys. 97: 42-49Itti E. Meignan M. Berriolo-Riedinger A. et al.

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

Eur J Nucl Med Mol Imag. 40: 1312-1320Hasenclever D. Kurch L. Mauz-Körholz C. et al.

qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Eur J Nucl Med Mol Imag. 41: 1301-1308van Diessen J. De Ruysscher D. Sonke J.J. et al.

The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).

Radiother Oncol. 131: 166-173Cooke S. De Ruysscher D. Reymen B. et al.

The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC.

Radiother Oncol. 152: S345-S346Nestle U. Schimek-Jasch T. Kremp S. et al.

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.

Lancet Oncol. 21: 581-592Greally M. Chou J.F. Molena D. et al.

Positron-Emission Tomography Scan–Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.

J Thorac Oncol. 14: 540-546Goodman K.A. Ou F.-S. Hall N.C. et al.

Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.

J Clin Oncol. 39: 2803-2815Cotter S.E. Grigsby P.W. Siegel B.A. et al.

FDG-PET/CT in the evaluation of anal carcinoma.

Int J Radiat Oncol Biol Phys. 65: 720-725Nguyen B.T. Joon D.L. Khoo V. et al.

Assessing the impact of FDG-PET in the management of anal cancer.

Radiother Oncol. 87: 376-382Kachnic L.A. Winter K. Myerson R.J. et al.

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.

Int J Radiat Oncol Biol Phys. 86: 27-33Friedman D.L. Chen L. Wolden S. et al.

Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031.

J Clin Oncol. 32: 3651-3658Radford J. Illidge T. Counsell N. et al.

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma.

N Engl J Med. 372: 1598-1607Borchmann P. Plütschow A. Kobe C. et al.

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 22: 223-234Keller F.G. Castellino S.M. Chen L. et al.

Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.

Cancer. 124: 3210-3219Pfreundschuh M. Christofyllakis K. Altmann B. et al.

Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.

J Clin Oncol. 35: 7506Held G. Murawski N. Ziepert M. et al.

Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma.

J Clin Oncol. 32: 1112-1118Bradley J.D. Hu C. Komaki R.R. et al.

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer.

J Clin Oncol. 38: 706-714Bradley J.D. Paulus R. Komaki R. et al.

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p.

Lancet Oncol. 16: 187-199Kong F.-M. Ten Haken R.K. Schipper M. et al.

Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer.

JAMA Oncol. 3: 1358Mahasittiwat P. Yuan S. Xie C. et al.

Metabolic Tumor Volume on PET Reduced More than Gross Tumor Volume on CT during Radiotherapy in Patients with Non-Small Cell Lung Cancer Treated with 3DCRT or SBRT.

J Radiat Oncol. 2: 191-202Kong F.-M.S. Hu C. Ten Haken R. et al.

NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).

J Clin Oncol. 39: 8548Yuan S. Yu Q. Wang S. et al.

Individualized Adaptive Radiotherapy versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601.

Int J Radiat Oncol Biol Phys. 108: S105

Towards enhanced PET quantification in clinical oncology.

Br J Radiol. 91: 20170508

Understanding the standardized uptake value, its methods, and implications for usage.

J Nucl Med. 45: 1431-1434Rosenbaum S.J. Lind T. Antoch G. et al.

False-Positive FDG PET Uptake−the Role of PET/CT.

Eur Radiol. 16: 1054-1065Oderinde O.M. Shirvani S.M. Olcott P.D. et al.

The technical design and concept of a PET/CT linac for biology-guided radiotherapy.

Clinical and Translational Radiation Oncology. 29: 106-112

Review of F-FDG Synthesis and Quality Control.

Biomed Imaging Interv J. 2: e57Tian S. Sethi I. Yang X. et al.

Characterization of Inter-Fraction 18-FDG PET Variability During Lung SBRT: Results of a Prospective Pilot Study.

Int J Radiat Oncol Biol Phys. 105: E536Tian S. Switchenko J. Yang X. et al.

Increased 18F-FDG Metabolic Activity during Lung SBRT Predicts Risk of Disease Progression: Results from a Prospective Study of Serial Inter-Fraction PET/CTs.

Int J Radiat Oncol Biol Phys. 108: S59-S60Ballinger J. Gnanasegaran G.

F-FDG and Non-FDG PET Radiopharmaceuticals.

in: PET/CT imaging. 18. Springer, New York City: 27-31